Taking toll: Lipid A mimetics as adjuvants and immunomodulators

Trends in Microbiology

Volumn 10, Issue 10, 2002, Pages

  Persing, David H ^a,b   Coler, Rhea N ^b   Lacy, Michael J ^c   Johnson, David A ^c   Baldridge, Jory R ^c   Hershberg, Robert M ^a,b   Reed, Steven G ^a,b  

^a GLAXOSMITHKLINE   (United States)

^b INFECTIOUS DISEASE RESEARCH INSTITUTE   (United States)

^c NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADJUVANT; IMMUNOMODULATING AGENT; LIPID A; MPL; RC 544; RECOMBINANT PROTEIN; RECOMBINANT VACCINE; TOLL LIKE RECEPTOR 4; UNCLASSIFIED DRUG;

DRUG STRUCTURE; HUMAN; IMMUNIZATION; IMMUNOMODULATION; INFECTION RESISTANCE; LEISHMANIA; LEISHMANIASIS; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL; REVIEW;

ADJUVANTS, IMMUNOLOGIC; ANIMALS; DROSOPHILA PROTEINS; FEMALE; IMMUNITY, NATURAL; LEISHMANIASIS; LIPID A; MEMBRANE GLYCOPROTEINS; MICE; MOLECULAR MIMICRY; MOLECULAR STRUCTURE; MUCOUS MEMBRANE; RECEPTORS, CELL SURFACE; TOLL-LIKE RECEPTOR 4; TOLL-LIKE RECEPTORS; VACCINATION;

ANIMALIA; PROTOZOA;

EID: 0036789814     PISSN: 0966842X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0966-842X(02)02426-5     Document Type: Review

References (29)

1. Rock F.L., et al. A family of human receptors structurally related to Drosophila Toll. Proc. Natl. Acad. Sci. U. S. A. 95:1998;588-593.
2. Ulevitch R.J. Toll gates for pathogen selection. Nature. 401:1999;755-756.
3. Ulevitch R.J. Molecular mechanisms of innate immunity. Immunol. Res. 21:2000;49-54.
4. Ouellette A.J., et al. Characterization of luminal paneth cell α-defensins in mouse small intestine: attenuated antimicrobial activities of peptides with truncated amino termini. J. Biol. Chem. 275:2000;33969-33973.
5. Han J., Ulevitch R.J. Emerging targets for anti-inflammatory therapy. Nat. Cell Biol. 1:1999;E39-E40.
6. Kaisho T., Akira S. Toll-like receptors as adjuvant receptors. Biochim. Biophys. Acta. 1589:2002;1-13.
7. Poltorak A., et al. Defective LPS signaling in C3H/HeJ and C57BL/10ScCr mice: mutations in Tlr4 gene. Science. 282:1998;2085-2088.
8. Poltorak A., et al. Physical contact between lipopolysaccharide and toll-like receptor 4 revealed by genetic complementation. Proc. Natl. Acad. Sci. U. S. A. 97:2000;2163-2167.
9. Ulevitch R.J. Endotoxin opens the Tollgates to innate immunity. Nat. Med. 5:1999;144-145.
10. Thoelen S., et al. A prophylactic hepatitis B vaccine with a novel adjuvant system. Vaccine. 19:2001;2400-2403.
11. Bienzle U., et al. Successful hepatitis B vaccination in patients who underwent transplantation for hepatitis B virus-related cirrhosis: preliminary results. Liver Transpl. 8:2002;562-564.
12. Baldridge J.R., Crane R.T. Monophosphoryl lipid A (MPL) formulations for the next generation of vaccines. Methods. 19:1999;103-107.
13. Baldridge J.R., et al. Monophosphoryl lipid A enhances mucosal and systemic immunity to vaccine antigens following intranasal administration. Vaccine. 18:2000;2416-2425.
14. Ulrich J.T., Myers K.R. Monophosphoryl lipid A as an adjuvant. Past experiences and new directions. Pharm. Biotechnol. 6:1995;495-524.
15. Reed S.G. Leishmaniasis vaccination: targeting the source of infection. J. Exp. Med. 194:2001;F7-F9.
16. Choi C.M., Lerner E.A. Leishmaniasis: recognition and management with a focus on the immunocompromised patient. Am. J. Clin. Dermatol. 3:2002;91-105.
17. Ashford R.W. The leishmaniases as emerging and reemerging zoonoses. Int. J. Parasitol. 30:2000;1269-1281.
18. Skeiky Y.A., et al. LeIF: a recombinant Leishmania protein that induces an IL-12-mediated Th1 cytokine profile. J. Immunol. 161:1998;6171-6179.
19. Webb J.R., et al. Human and murine immune responses to a novel Leishmania major recombinant protein encoded by members of a multicopy gene family. Infect. Immun. 66:1998;3279-3289.
20. Webb J.R., et al. Molecular characterization of the heat-inducible LmSTI1 protein of Leishmania major. Mol. Biochem. Parasitol. 89:1997;179-193.
21. Webb J.R., et al. Molecular cloning of a novel protein antigen of Leishmania major that elicits a potent immune response in experimental murine leishmaniasis. J. Immunol. 157:1996;5034-5041.
22. Doherty T.M., et al. Oral vaccination with subunit vaccines protects animals against aerosol infection with Mycobacterium tuberculosis. Infect. Immun. 70:2002;3111-3121.
23. Beutler B., Poltorak A. Positional cloning of LPS, and the general role of toll-like receptors in the innate immune response. Eur. Cytokine Netw. 11:2000;143-152.
24. Hemmi H., et al. A Toll-like receptor recognizes bacterial DNA. Nature. 408:2000;740-745.
25. Bauer S., et al. Human TLR9 confers responsiveness to bacterial DNA via species-specific CpG motif recognition. Proc. Natl. Acad. Sci. U. S. A. 98:2001;9237-9242.
26. Johnson D.A., et al. Synthesis and biological evaluation of a new class of vaccine adjuvants: aminoalkyl glucosaminide 4-phosphates (AGPs). Bioorg. Med. Chem. Lett. 9:1999;2273-2278.
27. Brandenburg K., et al. Investigation into the acyl chain packing of endotoxins and phospholipids under near physiological conditions by WAXS and FTIR spectroscopy. J. Struct. Biol. 128:1999;175-186.
28. Brandenburg K., et al. Conformation and fluidity of endotoxins as determinants of biological activity. Prog. Clin. Biol. Res. 392:1995;167-182.
29. Seydel U., et al. Phase behavior, supramolecular structure, and molecular conformation of lipopolysaccharide. Immunobiology. 187:1993;191-211.